Upstream Bio, Inc. Common Stock (UPB) is a publicly traded Healthcare sector company. As of May 21, 2026, UPB trades at $8.41 with a market cap of $463.11M and a P/E ratio of -3.12. UPB moved +4.61% today. Year to date, UPB is -67.81%; over the trailing twelve months it is -7.89%. Its 52-week range spans $5.14 to $33.68. Analyst consensus is strong buy with an average price target of $45.00. Rallies surfaces UPB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Upstream Bio Holds $294.6M Cash, Targets Q1 2027 Phase 3 Asthma and CRSwNP Trials: Upstream Bio ended Q1 2026 with $294.6 million in cash, funding operations through 2027, and recorded $36.6 million in R&D expenses. The company targets FDA End-of-Phase 2 meetings in mid-2026, Phase 3 asthma and CRSwNP trials in Q1 2027, and expects COPD Phase 2 data in H2 2027.
| Metric | Value |
|---|---|
| Price | $8.41 |
| Market Cap | $463.11M |
| P/E Ratio | -3.12 |
| EPS | $-2.66 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.68 |
| 52-Week Low | $5.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.85M |
| Net Income | $-143.44M |
| Gross Margin | 0.00% |
8 analysts cover UPB: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.00.